von Hippel-Lindau-binding protein 1 (VBP1) physically interacts with pVHL, an E3-ubiquitin ligase, which degrades HIF-1a in an oxygendependent manner. HIF-1 is a key regulator of adaptive responses to a lack of oxygen that controls glucose metabolism, angiogenesis, proliferation, invasion, and metastasis. However, the role of VBP1 in pVHL-mediated degradation of HIF-1a is not yet known. In this study, we show that VBP1 enhances the stability of pVHL and facilitates pVHL-mediated ubiquitination of HIF-1a. Furthermore, VBP1 suppresses HIF-1a-induced epithelialmesenchymal transition in vitro and tumor metastasis in vivo. These findings suggest that VBP1 is a bona fide tumor suppressor protein associated with HIF-1a regulation.
Introduction
Metastasis is the main cause of death for most cancer patients [1] . Epithelial-mesenchymal transition (EMT), a dynamic cellular phenomenon by which cells lose their epithelial characteristics and take on properties of mesenchymal cells, is the central process of metastasis. EMT is induced by transcription factors including Snail, Slug, ZEB1, SIP1, and Twist [2, 3] . EMTassociated transcription factors are regulated by diverse tumor microenvironments, such as inflammation, oxidative stress, and hypoxia in cancer cells [4] .
Hypoxia, a state of low oxygen levels, is one of the leading causes of EMT and metastasis initiation and is a common feature of many solid tumors. In hypoxia, cells change their gene expression pattern through oxygen response pathway mediated by hypoxia-inducible factor-1 (HIF-1). HIF-1 is a key survival protein that controls adaptive responses to a lack of oxygen by increasing proliferation, invasion, and metastasis in several types of cancer. HIF-1 is a heterodimer consisting of oxygen-regulated HIF-1a and constitutively expressed HIF-1b [5] [6] [7] .
While the transcription of HIF-1b is not affected by oxygen level, HIF-1a protein is tightly regulated by oxygen level and various post-translational modifications such as hydroxylation, phosphorylation, acetylation, and sumoylation [8] . In normoxic conditions, the half-life of HIF-1a is decreased through the hydroxylation of two proline residues by oxygen-sensitive prolyl hydroxylase domain-containing proteins (PHDs). The hydroxylated form of HIF-1a interacts with the von Hippel-Lindau protein (pVHL), which recruits elongin B, elongin C, Cullin2, and Rbx1 to form the multimeric E3 ubiquitinprotein ligase complex (VBC complex) that executes the ubiquitination and the proteasomal degradation of HIF-1a. Under hypoxic conditions, however, the hydroxylation of HIF-1a no longer occurs. Instead, stabilized HIF-1a translocates into the nucleus and heterodimerizes with HIF-1b. Therefore, pVHL plays a key role in HIF-1a regulation in the presence of oxygen [9] [10] [11] [12] .
The von Hippel-Lindau-binding protein 1 (VBP1) has been initially isolated as a novel protein that binds to the C-terminal end of pVHL [13, 14] . VBP1 (also known as prefoldin 3), a subunit of the prefoldin complex, is a jellyfish-like heterohexameric cochaperone. The prefoldin complex cooperates with the chaperonin T-complex protein-1-ring-complex (TRiC) to facilitate folding of newly synthesized proteins, such as actin and tubulin [15, 16] . Prefoldin has various functions, besides fine-tuning of the protein folding process via its interaction with TRiC. Accumulating evidence indicates that each prefoldin subunit has its own individual roles. PFD2 and PFD6 form a prefoldin-like complex which interacts with RNA polymerase II and stimulates transcription elongation [17, 18] . PFD5, also known as MM-1, represses c-Myc through inducing proteasome-dependent degradation and recruiting the TIF1b correpressor and the histone deacetylase HDAC1-mSin3 complex [19] . VBP1 has a variety of functions including transcriptional regulation and proteasomal degradation. VBP1 directly interacts with hepatitis B virus X protein (HBx) and facilitates HBx-induced NF-jB activation [20] . Furthermore, VBP1 is involved in pVHL-mediated proteasomal degradation of proteins such as hMSH4 and HIV integrase (IN) [21, 22] . HIF-1a is the most important degradation target of pVHL, hence, we can speculate that VBP1 may affect pVHL-mediated degradation of HIF-1a.
Here, we showed that VBP1 facilitates pVHLmediated proteasomal degradation of HIF-1a. VBP1 affects the protein level and the transcriptional activity of HIF-1a through enhancing pVHL stability by blocking the ubiquitination of pVHL. In addition, VBP1 represses tumor metastasis induced by HIF-1a-mediated EMT. Therefore, our results demonstrate that VBP1 is a new tumor suppressor which stabilizes pVHL to repress HIF-1a.
Results

VBP1 increases the pVHL-mediated regulation of HIF-1a
von Hippel-Lindau-binding protein 1 binds to pVHL, and pVHL degrades HIF-1a by ubiquitination. Therefore, we speculated that VBP1 might affect pVHLmediated ubiquitination and degradation of HIF-1a. In this context, HCT116 human colon carcinoma cells were transfected with expression plasmids for VBP1 and pVHL (30 KDa) . pVHL has two isoforms, 19 KDa and 30 KDa proteins, and both isoforms display tumor suppressor ability to regulate HIF-1a [23] . As expected, pVHL reduced the protein levels of endogenous HIF-1a. However, surprisingly, VBP1 along with pVHL, dramatically reduced the HIF-1a levels (Fig. 1A) . Since VBP1 reduced the HIF-1a levels in HCT116 cells, we examined whether VBP1 reduces the HIF-1a levels in VHL-null renal carcinoma cells, 786-O, which have truncated HIF-1a mRNA and produce aberrantly migrating HIF-1a proteins [24, 25] . 786-O cells were transfected with expression plasmids for HIF-1a, pVHL, and VBP1. When pVHL was absent, VBP1 failed to decrease the HIF-1a levels, whereas in the presence of pVHL, VBP1 more decreased the HIF1a levels than pVHL alone (Fig. 1B) . These results indicate that VBP1 decreases the HIF-1a levels in a pVHLdependent manner.
To determine whether HIF-1a is regulated by VBP1 at post-translational level, we tested half-life of HIF1a using protein synthesis inhibitor cycloheximide (CHX). VBP1 and pVHL synergistically degraded HIF-1a more rapidly than pVHL alone (Fig. 1C) . In order to confirm the role of VBP1 in regulating HIF1a levels, we performed the ubiquitination assay. Figure 1D shows that pVHL increased the ubiquitination of HIF-1a and VBP1 further increased the ubiquitination of HIF-1a. These results suggest that VBP1 facilitates pVHL-mediated ubiquitination of HIF-1a.
Subsequently, to study how VBP1 enhances pVHLmediated ubiquitination of HIF-1a, we tested the physical interaction between VBP1 and HIF-1a. Based on the immunoprecipitation assay, VBP1 and HIF-1a did not physically interact with each other (Fig. 1E) . Although VBP1 did not bind to HIF-1a, it is possible that VBP1 regulates the interaction between pVHL and HIF-1a because VBP1 interacts with pVHL. In vitro binding experiment exhibited that VBP1 did not enhance the physical interaction between pVHL and HIF-1a (Fig. 1F) . However, interestingly, we found that VBP1 markedly enhanced the interaction between pVHL and HIF-1a in cells, possibly due to Results represent the mean AE SD (n = 6). Statistical significance was evaluated using Student's t-test (*, P < 0.05; **, P < 0.01; ***, P < 0.001). (B) pVHL null 786-O cells were transfected with plasmids expressing GST-HIF-1a, HA-pVHL and Flag-VBP1. At 48 h after transfection, cells were harvested and analyzed by western blotting with the indicated antibodies. Results represent the mean AE SD (n = 3). Statistical significance was evaluated using Student's t-test (**, P < 0.01; ***, P < 0.001; ns, nonsignificant). the increased amount of pVHL in the presence of VBP1 (Fig. 1G ). Collectively, these data suggest that VBP1 enhances pVHL-induced HIF-1a ubiquitination and degradation by increasing the amount of pVHL.
VBP1 stabilizes pVHL through blocking ubiquitination
Unexpectedly, we observed that the pVHL level is elevated in VBP1-expressing cells compared to control cells. Thus, to explore this observation, we tested whether VBP1 could regulate pVHL protein levels. VBP1 is a subunit of the prefoldin chaperon complex, so it is possible that VBP1 may stabilize pVHL. Interestingly, VBP1 increased endogenous pVHL levels ( Fig. 2A) . Moreover, VBP1 shRNA markedly reduced pVHL protein levels ( Fig. 2B ). These results suggest that VBP1 enhances pVHL protein stability. Hence, to confirm that VBP1 upregulates pVHL stability, we performed the CHX chase assay. As shown in Fig. 2C , VBP1 increased the amount of endogenous pVHL levels and prolonged the half-life of pVHL. Next, to understand how VBP1 upregulates pVHL protein stability, we next examined whether VBP1 regulates pVHL ubiquitination. As shown in Fig. 2D , polyubiquitination of pVHL was dramatically reduced by VBP1. These results demonstrate that VBP1 stabilizes pVHL by downregulating its ubiquitinational degradation.
VBP1 stabilizes pVHL in a TRiC-independent manner
It was previously reported that the folding of pVHL is mediated by TRiC chaperonin and VBP1 is one subunit of the prefoldin complex. Thus, VBP1 might stabilize pVHL through cooperating with TRiC chaperonin as a prefoldin cochaperone. pVHL has two distinct TRiC binding regions, box1 (amino acids 116-119; LWLF) and box2 (amino acids 148-155; FANITLPV). Alanine substitution mutations of each box are sufficient to disrupt the interaction between pVHL and TRiC, along with pVHL and elongin BC [26] . Hence, to explore whether the stabilization of pVHL by VBP1 is associated with TRiC, we constructed pVHL box1A mutant, which has the substitution of four consecutive alanine residues in box1 (Fig. 3A ). Next, we tested whether VBP1 could stabilize pVHL box1A mutant. Interestingly, VBP1 increased the pVHL box1A mutant protein levels, just like pVHL wild-type (Fig. 3B ). Given that TRiC is necessary for assembly of functional VBC complex, we also tested whether VBP1 increases the assembly of VBC. As shown in Fig. 3C , VBP1 did not increase the interaction between elongin C and both pVHL wild-type and box1A mutant. Taken together, these data indicate that VBP1 stabilizes the pVHL protein level in a TRiC-independent manner.
VBP1 decreases HIF-1a level and activity through stabilizing pVHL
Considering that VBP1 increases the stability of pVHL, we investigated the effect of VBP1 on the level and the functional activity of HIF-1a. Consequently, we found that VBP1 increased the level of endogenous pVHL and reduced the endogenous HIF-1a levels (Fig. 4A) . We also observed that VBP1 shRNA decreased the pVHL level and increased the level of HIF-1a (Fig. 4B) . To exclude the possibility that VBP1 directly regulates HIF-1a in mRNA level, we quantified the endogenous HIF1A mRNA levels by quantitative real-time PCR (qRT-PCR) in cells expressing VBP1 and VBP1 shRNA. As shown in Fig. 4C , HIF1A mRNA levels were not changed by VBP1
. Furthermore, to demonstrate that VBP1 also regulates pVHL and HIF-1a under hypoxic conditions, cells were transfected with Flag-VBP1 plasmid for 24 h and then exposed to hypoxic condition. Figure 4D reveals that VBP1 also regulates the level of pVHL and HIF-1a under hypoxic conditions. Next, we examined whether VBP1 regulates HIF-1a transcriptional activity through pVHL stabilization. The effect of VBP1 on HIF-1a transcriptional activity was analyzed by the luciferase assay using HIF-1-responsive elements (HRE)-Luc as reporter. VBP1 markedly repressed HIF-1a transcriptional activity and VBP1 shRNA increased HIF-1a transcriptional activity (Fig. 4E) . Overall, these data indicate that VBP1 represses protein stability and transcriptional activity of HIF-1a through stabilizing pVHL under normal and hypoxic conditions.
VBP1 represses EMT pathway through reducing HIF-1a transcriptional activity
We next analyzed the functional consequences of the reduced HIF-1a transcriptional activity by VBP1. HIF-1a has been implicated in EMT to promote tumor invasion and metastasis through transactivating EMT transcription factors. Particularly, Twist is one of the EMT-inducing transcription factors directly transactivated by HIF-1a [27] . Reduced expression of HIF-1a induced by VBP1 might attenuate HIF-1a-mediated EMT process. So, to confirm the role of VBP1 in EMT, we first examined whether VBP1 regulates Twist promoter activity. Twist-Luc promoter activity was elevated by HIF-1a, which was, in turn, repressed by VBP1 in a dose-dependent manner (Fig. 5A) . Next, we determined the effect of VBP1 on the expression of EMT markers associated with HIF1a. Twist, a basic helix-loop-helix transcription factor, has been shown to induce EMT through the repression cells expressing Flag-VBP1 were exposed to hypoxic conditions for 6 h. Cell extracts were analyzed by western blotting with anti-Flag, anti-VHL, anti-HIF-1a, and anti-a-tubulin antibodies. (E) HCT116 cells were transfected with HRE-Luciferase reporter plasmid and expression plasmids for HIF-1a, VBP1, and VBP1 shRNA. At 48 h after transfection, HRE activities were determined via the Dual-Luciferase Reporter Assay System. Results represent the mean AE SD (n = 3). Statistical significance was evaluated using Student's t-test (***, P < 0.001).
of E-cadherin and the activation of vimentin, Ncadherin, and fibronectin [28] . E-cadherin is a wellknown epithelial marker, while vimentin is a typical mesenchymal marker. Therefore, we checked the expression levels of the EMT markers in VBP1 expressing HCT116 cells. Figure 5B shows that VBP1 increased the level of E-cadherin and repressed the level of vimentin. To confirm the regulation of EMT markers by VBP1 is pVHL-dependent, we tested the effect of VBP1 on E-cadherin and vimentin in the presence of pVHL siRNA. As shown in Fig. 5C , pVHL siRNA reduced VBP1-induced stabilization of pVHL, elevated HIF-1a, reduced E-cadherin level, and elevated vimentin level. In contrast, VBP1 shRNA decreased the level of E-cadherin and increased the level of vimentin (Fig. 5D) . To confirm the regulation of EMT markers by VBP1 shRNA is HIF-1a-dependent, we also tested the effect of VBP1 shRNA on Ecadherin and vimentin in the presence of HIF-1a siRNA.
As expected, HIF-1a siRNA reduced VBP1 siRNAmediated increase of HIF-1a, elevated E-cadherin level, and reduced vimentin level (Fig. 5E) . Furthermore, VBP1 also increased E-cadherin under hypoxic conditions (Fig. 5F ). These results indicate that VBP1 represses the EMT pathway induced by HIF-1a through regulating pVHL.
VBP1 suppresses metastasis in vitro and in vivo
Increased cell motility and invasiveness are significant features of EMT and metastasis [29] . In order to demonstrate the role of VBP1 in cell migration, we performed the scratch wound healing assay and the Transwell invasion assay. In Fig. 6A , the wound healing assay revealed that VBP1 decreased the cell migration capacity, but VBP1 shRNA increased cell migration. Also, the Transwell invasion assay showed that the invasive property of HCT116 cells expressing VBP1 was significantly reduced, whereas that of VBP1-depleted HCT116 cells was enhanced (Fig. 6B) . Next, we investigated the role of VBP1 in metastasis in vivo. Briefly, lung metastasis was analyzed in C57BL/6 mice at 3 weeks after tail veil injections, with either VBP1 or VBP1 shRNA expressing B16F10 mouse melanoma cells. The number of metastatic nodules in the lungs of mice in each group showed that VBP1 significantly decreased metastasis to the lung, while knockdown of VBP1 dramatically increased it compared to mock (Fig. 6C ). These data suggest that VBP1 strongly suppresses cell motility and tumor metastasis.
Discussion
Hypoxia-inducible factor 1a is a key player in tumor metastasis. HIF-1a activates the transcription of the genes associated with angiogenesis, gluconeogenesis, and EMT, a critical process of metastasis [5, 30] . HIF1a is elaborately regulated through diverse post-translational modification including hydroxylation associated with oxygen concentration [8] . pVHL, an E3 ubiquitin ligase of HIF-1a, has a crucial role in HIF1a regulation [9, 11] . However, the regulatory mechanism of pVHL has not been completely elucidated. In the present study, we demonstrated that VBP1 is a positive regulator protein of pVHL. We showed that VBP1 stabilizes pVHL through repressing pVHL ubiquitination. Currently, the mechanism by which VBP1 suppresses pVHL ubiquitination remains unclear. The newly synthesized nascent polypeptide chain of the microtubules is transferred to chaperonin TRiC, with the assistance of the cochaperone prefoldin complex [16] . It is known that TRiC is also required for proper folding of pVHL and that correctly folded pVHL, by TRiC, is assembled with elongin BC and forms a substrate receptor for the VBC ubiquitin ligase [31, 32] . However, experimental evidence to show how The invasion ability of cells was measured using Transwell cell culture chambers. (C) B16F10 mouse melanoma cell lines stably expressing either VBP1 or VBP1 shRNA were injected into the lateral tail vein of C57BL/6J mice (n = 5 per group). At 18 days after inoculation, metastasized lungs were analyzed. Statistical significance was evaluated using Student's t-test (*, P < 0.05; ***, P < 0.001).
prefoldin complex is associated with the transfer of pVHL to TRiC has not yet been reported. Given that VBP1 is one subunit of the prefoldin complex and binds to pVHL, we speculated that prefoldin complex and its subunit VBP1 might be associated with transferring unfolded pVHL to TRiC like microtubules. However, our data suggest that VBP1 alone stabilizes pVHL in a TRiC-independent manner. We showed that VBP1 also stabilizes pVHL box1A mt, which is defective at binding to TRiC. Moreover, VBP1 does not affect the formation of the VBC complex. pVHL is ubiquitinated by Rbx1 in vitro, without elongin B and C [33] . We also tested the possible roles of Rbx1 and found that the mechanism of pVHL deubiquitination by VBP1 is not associated with Rbx1 (data not shown). Future studies are required to clarify this mechanism in more detail.
Our results provide new evidence that shows VBP1 enhances the regulatory function of pVHL on HIF-1a degradation. Recently, it has been reported that VBP1 facilitates the function of pVHL, through direct binding with hMSH4 and HIV IN, for proteasomal degradation mediated by pVHL and recruits pVHL to them [21, 22] . Our results showed that VBP1 does not directly interact with HIF-1a, although VBP1 increases the formation of the pVHL-HIF-1a complex through pVHL stabilization.
In the present study, VBP1 stabilizes pVHL and destabilizes HIF-1a by elevating pVHL-induced HIF1a ubiquitination. HIF-1a directly transactivates the expression of EMT-inducing transcription factors, particularly Twist [27] . Twist upregulates vimentin and downregulates E-cadherin [28] . Our data showed that VBP1 regulates the expression of HIF-1a-mediated EMT marker proteins. Also, we provide evidence that VBP1 represses the metastatic ability of cancer cells. These results suggest that VBP1 could suppress tumor metastasis.
Recent studies provide evidences that each subunit of prefoldin has its own individual roles. Especially, it seems that the PFD subunits are associated with tumorigenesis. PFD5 represses c-Myc through recruiting the histone deacetylase HDAC1-mSin3 complex, the ubiquitin ligase skp2-elongin B-elongin C-cullin2 complex for ubiquitination, and the Egr-1 repressor to the promoter of Wnt4, which is positively control c-Myc gene [19, 34, 35] . PFD4 inhibits cell growth and invasiveness [36] . PFD1 promotes tumor growth and metastasis through suppressing cyclin A expression [37] . Our findings support the association between tumorigenesis and PFD subunits.
Taken together, we suggest the new function of VBP1 is associated with pVHL. It is evident that VBP1 stabilizes pVHL and represses HIF-1a. In this study, we showed that VBP1 promotes HIF-1a ubiquitination and has a pivotal role in HIF-1a-induced EMT and metastasis.
Materials and methods
Cell culture and transfection HEK 293T, HCT116, 786-O, and B16F10 cells were maintained in DMEM supplemented with 10% FBS at 37°C in 5% CO 2 . 786-O cells were kindly provided by Cho-Rok Jung [38] . For a hypoxic environment, cells were incubated in a hypoxia chamber set to 1% O 2 and 5% CO 2 (Coy Laboratory Products, Grass Lake, MI, USA). Cells were transfected with PEI (Sigma-Aldrich, St. Louis, MO, USA) and Lipofectamine 3000 (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer's instruction.
Plasmids and siRNAs
The VBP1 coding DNA fragment was cloned into EcoRI and BamHI sites of pBICEP-CMV-1 (Sigma-Aldrich) to produce pBICEP-Flag-VBP1. The flag-fused VBP1 fragment from pBICEP-Flag-VBP1 was subcloned into retroviral vector pLXRN (Clontech, Mountain View, CA, USA) to produce the pLXRN-Flag-VBP1. The VBP1 shRNA plasmid was generated by inserting the oligonucleotide containing the specific shRNA target sequence (GTA-TAAGTTTATGGAACTC) into the pSUPER-retro-puro vector (Oligoengine, Seattle, WA, USA). The Twist-Luc construct was provided by Kou-Juey Wu [27] . pVHL box1A mutant was generated by site-directed mutagenesis of pEBG-pVHL using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) and confirmed through DNA sequencing. HIF-1a siRNA (siRNA no. 1068432), pVHL siRNA (siRNA no. 1161840), and control siRNA were purchased from Bioneer (Daejeon, Korea). siRNA-mediated gene knockdown was performed using Lipofectamine 3000 according to the manufacturer's instructions.
Western blot analysis and antibodies
Cell lysates were prepared in modified RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 0.5 mM DTT, 1 lgÁmL À1 aprotinin, 1 lgÁmL À1 leupeptin, and 1 lgÁmL À1 pepstatin). Then, the cell lysates and immunocomplexes were resolved on SDS/PAGE and transferred onto a PVDF membrane (Millipore, Burlington, MA, USA).
Immunoblotting was performed with the indicated antibodies. Antibodies against GST, His, HA, Myc, VBP1, pVHL, b-actin, a-tubulin, rabbit anti-goat IgG-HRP, goat antirabbit IgG-HRP, and goat anti-mouse IgG-HRP were purchased from Santa Cruz (Dallas, TX, USA). Anti-Flag antibody was purchased from Sigma-Aldrich. Antibodies against E-cadherin and vimentin were purchased from Cell Signaling Technology. Anti-HIF-1a antibody was purchased from Millipore.
GST pulldown assay
Transiently transfected HEK 293T cells were lysed in modified RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Nadeoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, and 1 mM Na 3 VO 4 ) supplemented with 1X protease inhibitor cocktail (GenDEPOT, Barker, TX, USA) at 4°C for 30 min. Cell lysates were incubated overnight with GlutathioneSepharose 4B beads (Incospharm, Daejeon, Korea) at 4°C. The bead complexes were washed three times with modified RIPA buffer and bound proteins were analyzed by SDS/ PAGE followed by western blotting.
In vitro binding assay
In vitro binding assay was performed as previously described [39, 40] . Briefly, His, His-VBP1, GST, and GST-HIF-1a were expressed in E. coli BL21 cells. The cell extracts expressing His and His-VBP1 were prepared by ultrasonication and incubated with Ni-nitrilotriacetic acid (Incospharm) to purify His-fusion protein. The cell extracts expressing GST and GST-HIF-1a were incubated with Glutathione-Sepharose 4B resin (Incospharm). GST and GST-HIF-1a immobilized resins were washed five times with cold PBS. The resulting immobilized GST resins were mixed with the lysates of HCT116 cells expressing HApVHL, and incubated with purified His or His-VBP1 proteins. The resins were washed five times with cold PBS, denatured with SDS sample buffer, and analyzed by SDS/ PAGE followed by western blotting.
Cycloheximide chase assay
Protein stability was determined by treating the cells with 400 lM cycloheximide (Tocris Bioscience, Bristol, UK). Cell lysates were prepared at indicated time points and analyzed by western blotting.
Ubiquitination assay
Before harvest, cells were treated with 20 lM MG-132 (AG scientific, San Diego, CA, USA) for 4 h. Cells were lysed with modified RIPA buffer containing MG-132 and pulled down with Glutathione-Sepharose 4B beads. The bead complexes were resolved by SDS/PAGE and western blotting was performed with the indicated antibodies.
Luciferase assay
The luciferase activities were measured by using a Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer's instruction. Firefly luciferase activity was normalized to Renilla luciferase activity. At 24 h after transfection, the luciferase assay was performed.
RNA isolation and quantitative real-time PCR
Total cellular RNA was isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The cDNA was synthesized from 1 lg of cellular RNA using oligo (dT) primers and the AccuPower RT PreMix (Bioneer 
Stable cell line
In order to establish stable B16F10 cell lines expressing VBP1 or VBP1 shRNA, each retroviral expression plasmid was constructed and transfected into HEK 293T cells, along with retroviral packaging vectors. At 48 h after transfection, recombinant retroviruses were collected and infected to HCT116 and B16F10 cells in the presence of 10 lgÁmL À1 polybrene for 12 h. At 48-72 h after infection, cells were selected by G418 and puromycin to obtain pools of stable cell lines.
Wound healing assay
B16F10 cells were seeded in six-well culture plates at a density of 3 9 10 5 cellsÁmL À1 and grown overnight. At 24 h after transfection, wounds were generated in confluent cells. The area covered by the migrating cells was measured using IMAGE J (NIH, Rockville, MD, USA) software by comparison of the same fields between 0 and 18 h. The experiments were repeated three times.
Matrigel invasion assay
After overnight serum starvation, 0.5 9 10 5 HCT116 cells were suspended in serum-free DMEM and seeded in the upper chamber of Matrigel (Corning Inc., Corning, NY, USA)-coated Transwell filters (8-lm pore) (Merck Millipore). The medium, containing 10% serum, was placed in the lower chamber and incubated at 37°C for 24 h. Noninvading cells remaining on the upper surface of the filter were removed. The cells on the lower surface of the filter were fixed with 4% formaldehyde and permeabilized with 100% methanol for 20 min. Invaded cells were stained with Giemsa and counted under a microscope. Experiments were independently repeated three times.
In vivo pulmonary metastasis assay
Male C57BL/6J mice (5-weeks old) were purchased from the Damul Science (Daejeon, Korea). The animal facilities and experiments were in accordance with local institutional guidelines for animal welfare and were approved by the Institutional Animal Care and Use Committee of Chungnam National University. The mice were divided into three groups (n = 5) and injected with B16F10 cells (5 9 10 5 cells/0.1 mL) via their tail veins. All animal experimental procedures were performed under anesthesia using isoflurane inhalation. At 18 days after injection, the mice were sacrificed by CO 2 euthanasia and their lungs were fixed in formaldehyde. The number of B16F10 colonies on the surface of each lung was determined by visual inspection.
Densitometric analysis of western blot
Scanning densitometric values of each western blot images were obtained using the IMAGE J gel analysis tool. Protein levels were normalized to the loading control (a-tubulin).
Statistical analysis
Statistical comparisons of results were evaluated by one-way analysis of variance (ANOVA) followed by Student's t-test for unpaired values. Data are expressed as means AE standard deviation and P < 0.05 was considered statistically significant. Levels of statistical significance are indicated by asterisks (*, P < 0.05; **, P < 0.01; or ***, P < 0.001; ns, nonsignificant).
